A Rare Case of a Metastatic Gastrointestinal Stromal Tumor (GIST): a Case Report and Review of the Literature

Saraireh, Hamzeh; Tayyem, Obada; Asad, Omar Al; Nawgiri, Ranjana; Alawin, Issam

doi:10.1007/s12029-017-0037-4

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, when intracranial GIST metastasis occurs, it usually affects the nervous system, resulting in dizziness, headache, memory impairment, loss of sensation and inability to move a single limb, the inability to maintain body balance and abnormal gait and posture, along with a series of neurological crements (27,32,35,40,51,61,70,87,87,92,93). In cases of bone metastasis, pain manifests in the affected bone area (29,37,48,52,53,63,69,75,80,94,95), in cases of skeletal muscle involvement, a mass can be palpated in the affected area (34,49,71,72,79), and when metastasis occurs deep in the bone marrow, anemia may be present (96). Furthermore, when GIST metastasizes to the lungs, signs and symptoms that may be observed include dyspnea, blood in the sputum, coughing and shortness of breath (18,85,88,97).…”

Section: Diagnosis Of Rare Site Metastasis Of Gistmentioning

confidence: 99%

Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)

Liang

Kong

2022

Oncol Lett

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIST) are the most common stromal-derived tumors of the gastrointestinal tract and have a potential metastatic capacity in almost half of all cases, with the most common sites of metastasis being the liver and peritoneum. However, there is evidence that GIST metastasizes to sites other than the liver and peritoneum, which poses challenges for clinical diagnosis and treatment. Therefore, the Cochrane and Medline databases were searched via PubMed in July 2022 using relevant keywords to acquire the literature associated with the metastasis of GIST to rare sites published since from 2000 onwards. Study data comprising age, sex, primary location, metastatic site, mean survival time, clinical signs and symptoms, imaging, pathological features immunohistochemical indices, treatment and prognosis were recorded and analyzed. The 118 metastases at rare sites reported in the literature included bone (n=31), lung (n=10), lymph nodes (n=13), intracranial sites (n=13), skin and subcutaneous tissue (n=10), heart (n=7), skeletal muscle (n=7), orbit and choroid (n=6), pancreas (n=3), spleen (n=2), bone marrow (n=1), testis (n=3), scrotum (n=1), epididymis (n=1), penis (n=1), ovary (n=2), cervix (n=1), kidney (n=1), bladder (n=1), adrenal gland (n=2) and thyroid gland (n=2). From the reviewed studies, it may be concluded that when metastases from gastrointestinal stromal tumors occur at rare sites, the initial symptoms may help in the identification of these sites. In addition, the site-dependent imaging of different metastatic locations may further define the metastases, and the findings of pathological or immunohistochemical analyses may be used to confirm the diagnosis. Contents Introduction 2. Materials and methods3. Rare metastatic sites and basic characteristics of patients 4. Diagnosis of rare site metastasis of GIST 5. Therapy and prognosis for rare site GIST metastases 6.

show abstract